These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Oxygen therapeutic window induced by myo-inositol trispyrophosphate (ITPP)-Local pO2 study in murine tumors. Krzykawska-Serda M; Szczygieł D; Gaweł S; Drzał A; Szczygieł M; Kmieć MM; Mackiewicz A; Kieda C; Elas M PLoS One; 2023; 18(5):e0285318. PubMed ID: 37167239 [TBL] [Abstract][Full Text] [Related]
11. Increasing the oxygen load by treatment with myo-inositol trispyrophosphate reduces growth of colon cancer and modulates the intestine homeobox gene Cdx2. Derbal-Wolfrom L; Pencreach E; Saandi T; Aprahamian M; Martin E; Greferath R; Tufa E; Choquet P; Lehn JM; Nicolau C; Duluc I; Freund JN Oncogene; 2013 Sep; 32(36):4313-8. PubMed ID: 23045284 [TBL] [Abstract][Full Text] [Related]
12. Enhanced exercise capacity in mice with severe heart failure treated with an allosteric effector of hemoglobin, myo-inositol trispyrophosphate. Biolo A; Greferath R; Siwik DA; Qin F; Valsky E; Fylaktakidou KC; Pothukanuri S; Duarte CD; Schwarz RP; Lehn JM; Nicolau C; Colucci WS Proc Natl Acad Sci U S A; 2009 Feb; 106(6):1926-9. PubMed ID: 19204295 [TBL] [Abstract][Full Text] [Related]
13. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885 [TBL] [Abstract][Full Text] [Related]
14. Treatment of hypoxia-dependent cardiovascular diseases by myo-inositol trispyrophosphate (ITPP)-enhancement of oxygen delivery by red blood cells. Oknińska M; El-Hafny-Rahbi B; Paterek A; Mackiewicz U; Crola-Da Silva C; Brodaczewska K; Mączewski M; Kieda C J Cell Mol Med; 2020 Feb; 24(3):2272-2283. PubMed ID: 31957267 [TBL] [Abstract][Full Text] [Related]
15. Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity. Tanegashima T; Togashi Y; Azuma K; Kawahara A; Ideguchi K; Sugiyama D; Kinoshita F; Akiba J; Kashiwagi E; Takeuchi A; Irie T; Tatsugami K; Hoshino T; Eto M; Nishikawa H Clin Cancer Res; 2019 Aug; 25(15):4808-4819. PubMed ID: 31076547 [TBL] [Abstract][Full Text] [Related]
16. Decursin promotes HIF-1α proteasomal degradation and immune responses in hypoxic tumour microenvironment. Ge Y; Yoon SH; Jang H; Jeong JH; Lee YM Phytomedicine; 2020 Nov; 78():153318. PubMed ID: 32896707 [TBL] [Abstract][Full Text] [Related]
17. Failure of Inositol Trispyrophosphate to Enhance Highly Effective Radiotherapy of GL261 Glioblastoma in Mice. Iyengar S; Schwartz D Anticancer Res; 2017 Mar; 37(3):1121-1125. PubMed ID: 28314273 [TBL] [Abstract][Full Text] [Related]
18. Bu Fei Decoction attenuates the tumor associated macrophage stimulated proliferation, migration, invasion and immunosuppression of non-small cell lung cancer, partially via IL-10 and PD-L1 regulation. Pang L; Han S; Jiao Y; Jiang S; He X; Li P Int J Oncol; 2017 Jul; 51(1):25-38. PubMed ID: 28534943 [TBL] [Abstract][Full Text] [Related]
19. Myo-InositolTrisPyroPhosphate treatment leads to HIF-1α suppression and eradication of early hepatoma tumors in rats. Aprahamian M; Bour G; Akladios CY; Fylaktakidou K; Greferath R; Soler L; Marescaux J; Egly JM; Lehn JM; Nicolau C Chembiochem; 2011 Mar; 12(5):777-83. PubMed ID: 21370375 [TBL] [Abstract][Full Text] [Related]